BTG2015 CONFERENCE INFORMATION
CONFERENCE VENUE
China National Convention Center
No.7 Tianchen East Road, Chaoyang District, Beijing 100105 China
Tel:+86 10 8437 3300
(http://cnccchina.com/en)
CONFERENCE HOTEL China National Convention Center Grand Hotel.
Address:
Building 1, No. 8 Precincts,
Beichen West Road, Chaoyang District,
Beijing 100105, P R China
Tel: +86 10 8437 2008
Fax: +86 10 8437 0387
Email: cncc@cnccchina.com
Reservation Please Contact
Tel: +86 10 8437 0690
Fax: +86 10 8437 0691
Email: rv@cnccchina.com
http://www.cnccchina.com/en/hotel/default.aspx
The CNCC Grand Hotel is international standard 420 room property that is immediately adjacent to the China International Convention Center on the Olympic Green boulevard. It serves as the CNCC host hotel for most CNCC events.
ABOUT US
The APHCON (Asia-Pacific Hematology Consortium) is the official host of BTG2015 and presents the 6th International Hematologic Malignancies Conference: Bridging the Gap 2014 with our logistics partner, The Medal Group. Founded in 2007, the Society is a non-profit medical association committed to promoting discourse about and furthering the research of hematology.
HISTORY
After the great success of BTG2010, BTG2011, BTG2012, BTG2013 and BTG2014, we present the 6th international educational meeting in Asia devoted to "Hematologic Malignancies: Bridging the Gap 2015" to be held in Beijing, China on January 31-February 1, 2015. The Congress brings together leading authorities in Hematology Oncology to present the latest ground breaking findings on cutting edge research and novel treatments. The discussion forums provide an opportunity to integrate the latest pharmaceutical interventions. The conference targets hematologic malignancies in particular leukemia, lymphoma, and myeloma. The target audience is Southeast and Central Asia, Japan, Australia and the United States.
The BTG series is being held in the South East Asia sector since the year 2010. The very first conference was held in Singapore attended by 250 delegates and now has grown to the most important meeting in this region. The conference has been held in Hong Kong for year 2012 and 2013; in Taipei for year 2014 and BTG2015 will be held in Beijing in year 2015.
In its 5th year, BTG2014 was attended by over 350 delegates from 19 different countries. In addition small breakout sessions were held in the format of simultaneous workshops that were a great success among the attendees. There were over 100 submitted abstracts and one oral presentation was chosen for the plenary session. In addition, all the selected abstracts are published in the peer reviewed journal ‘Leukemia & Lymphoma’. BTG2014 also afforded platform APHCON Presidential dinner and follow up of Preceptorship award.
What is G.A.P?
Global Academic Programs (GAP) facilitates and administers MD Anderson's Sister Institution Network; the largest global network of cancer centers working collaboratively on research and education aimed at lessening the world's cancer burden.
You can stay informed by subscribing to GAP Connect, a weekly newsletter intended to engage and enable global collaborations in cancer research.
BRIDGING THE GAP - 2015
This congress will be a productive, interactive and educational experience for the attendees. Top researchers and practitioners from the world over will meet to discuss the current state - and future directions - of Hematologic Malignancies in the Asian sector and explore opportunities for collaborations in order to further the field. The event promises to be a unique medical education forum for the exchange of critical information as well as analyze the challenges faced by the practicing clinicians. It will feature didactic presentations and debates, in which experts will discuss some of the most challenging topics in leukemia, stem cell transplant and mobilization, myelodysplastic syndrome, lymphoma and myeloma, providing a thorough analysis of research breakthroughs and emerging data.
NEED ASSESSMENT BTG2015
1. Orientation to purpose and scope of the agenda:
Why the Project exists: Cancer is a leading cause of death in central and Southeast Asia. It is important to note that in most developed countries, cancer is the second largest cause of death after cardiovascular disease, and epidemiological evidence points to this trend emerging in the less developed world. This is particularly true in countries in "transition" or middle-income countries, such as in South America and Asia. Already more than half of all cancer cases occur in developing countries. Cancer alone accounts for 16% of all deaths in Asia and Hematologic malignancies are an increasing subset of the total cancer incidence rate. In the recent years great improvement in the field of Oncology has taken place with a rapid growth in trained oncologists and cancer centers as well as advancements in diagnostic technology. However, since the Asian healthcare community is geographically dispersed, it is often characterized by a lack of standardization of treatment and different philosophies of care. Given this fragmentation, there is a need to formalize and integrate conceptual knowledge, disease understanding, therapeutic agent intervention, diagnostic methodologies, supportive care, and management of complications.
Since Beijing, China is on the leading edge of medicine and especially oncology care, it is an ideal venue for promoting stronger understanding between practitioners and laboratory researchers from different fields and providing a platform for advancing daily clinical practice. This would in turn improve overall quality of cancer treatment, especially in terms of diagnosis and follow up of therapeutic strategies.
The proposed conference ‘6th International Hematologic Malignancies Conference ‘Bridging the Gap:2015’’ in Beijing, China to be held on Jan 31-Feb 1, 2015 is the results of the joint effort of the MDACC, Houston and the Peking University, Beijing. The key objective of this meeting is to lay foundation of a potentially growing relationship between US and SouthEast Asia in the field of malignant Hematology.
The main goals include:
i) Identify the existing need for the current medical education of the practicing hematologists with an Asian perspective, and build sessions to address the key areas of need.
ii) Construct methodology for promoting increased awareness, knowledge and integration of diagnostic tests into daily practice in the field of malignant hematology in the Asian sector including practice guidelines and the latest therapeutic agents.
iii) Encourage and provide opportunity for clinical and basic research in the field of malignant hematology.
2. How it is different: This is a unique, the first of its kind conference in Beijing where US and Asian speakers will share the same platform to address the local physicians and fellows in training. Create awareness regarding the disease concept, pathology, diagnosis, new therapeutic options and novel pharmaceutical interventions. This conference also, proposes to have open case discussions where the local physicians will get a chance to do case discussions in an open forum platform set up. This informal setting proposes to overcome any barriers and provide a conduit of open discussion, exchange of ideas, sharing of data and possible clinical collaborations. This congress will be an exciting, productive, interactive and educational experience for the attendees. Top researchers and practitioners from the world over will meet to discuss the current state – and future directions – of Hematologic Malignancies in the Asian sector and explore opportunities for collaborations in order to further the field. The event promises to be a unique medical education forum for the exchange of critical information as well as analyze the diagnostic and therapeutic challenges faced by the practicing clinicians. It will feature didactic presentations and debates, in which experts will discuss some of the most challenging topics in lymphoma, myeloma, immunotherapy and stem cell transplant, providing a thorough analysis of research breakthroughs and emerging data.
3. Strategic value is to supporters: Beijing, China has one of the fastest growing economies with a great opportunity for the pharmaceutical industry. Moreover, Beijing, China is very friendly to visitors and foreign nationals. It is very easy to travel to, easily accessible, strategically located in the center of Asia and Australia. Already, major US pharmaceuticals have established their centers in Beijing, China. By providing an educational platform, our supporters will gain an extra ordinary advantage over the competitors in terms of getting great exposure, able to deliver the updated data as well as educate the prescribing physicians about their product. Moreover, the conference will provide a unique and credible interaction with the meeting delegates in order to establish long term relationships.
By supporting one of the biggest and the first truly international Hematologic Malignancies Conference in SouthEast Asia, the sponsors get exposure to over 750 attendees, most of who are from Beijing, China, India, China, Australia, Beijing, China, Japan, Malaysia, Thailand, Vietnam, Indonesia, Taiwan, UAE, UK, Middle east, and the United States. The sponsors get an opportunity to support promotional luncheons and dinner symposiums. Also, there is opportunity for exhibit booths, where the sponsors are able to directly get in touch with the local oncologists which otherwise maybe onerous. Therefore, with one contribution, the pharmaceutical companies are able to really get a return on their investment by getting a tremendous exposure, advertisement, marketing opportunity, gather demographic data, educate the practicing oncologists regarding their latest innovations and possibly get access to other wise hard to reach doctors.
4. Most important topics for the target audience: The incidence and prevalence of Hematologic Malignancies are on a great increase in Asia. The proposed topics cover the pathology, diagnostic procedures and latest treatments including stem cell transplant and post transplant maintenance therapy. Most of all the speakers are internationally acclaimed and of great repute which has already generated enough enthusiasm that the RSVP to the SAVE THE DATE announcements has reached a number close to 500 attendees. The proposed topics are in need of an in depth education and understanding and since these diseases are on the rise, it gives the target audience a great resource to learn from the major thought leaders in the field.
5. Confirmation of facility resources for sponsorship: exhibit space specs, available rooms and capacity for ancillary activities: the New Otani Hotel is one of the premier locations for conferences in China. The conference venue can hold upto 2,000 people with very grandiose facilities. Most of the international meeting attendees will be able to stay at the Convention hotel itself ensuring their easy access to the conference area. There are over 600 guest rooms for the meeting attendees. Also, there is availability of the foyer area for the exhibit booths and poster display. They also have enough space for break out sessions as well as Lunch symposiums.
6. Description of target audience, current registration, and demographics: This conference is specifically designed for Hematologists, Oncologists, Transplant Oncologists, Radiation Oncologists, physicians-in-training, and healthcare professionals (nurses, pharmacists, etc) involved in and/or interested in hematologic malignancies and their management. Attendees are expected to be from Beijing, China, India, China, Hongkong, Australia, Beijing, China, Japan, Malaysia, Thailand, Vietnam, Indonesia, Taiwan, UAE, UK, Middle East, and the United States. The current pre-registration estimated number is around 1500.
7. Invited Speakers: Estimated 40 international and national experts (culled from a pool of ground-breaking researchers and practitioners) will address the congress.
8. CONFERENCE REGISTRATION INFORMATION: The registration fee to attend this conference includes two days of scientific sessions, workshops, lunch sessions, coffee breaks and corporate mini symposiums.
REGISTRATION FEE:
Regular Registration: NOV 16, 2014- JAN 18, 2015: USD 599
ON Site Registration: JAN30, 2015 - Feb 1, 2015: USD 699
REFUND POLICY: An administrative fee of USD 125 will be deducted from any cancellations made after NOV 30, 2014. No refunds will be made after January 15, 2015.
PRIVACY POLICY: All information collected during the registration process will remain confidential. No personal information will be shared. We take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. While we use encryption to protect sensitive information transmitted online, we also protect your information offline. Only employees who need the information to perform a specific job (for example, billing or customer service) are granted access to personally identifiable information. The computers/servers in which we store personally identifiable information are kept in a secure environment. We are the sole owners of the information collected on this site. We only have access to/collect information that you voluntarily give us via email or other direct contact from you. We will not sell or rent this information to anyone.
China National Convention Center
No.7 Tianchen East Road, Chaoyang District, Beijing 100105 China
Tel:+86 10 8437 3300
(http://cnccchina.com/en)
CONFERENCE HOTEL China National Convention Center Grand Hotel.
Address:
Building 1, No. 8 Precincts,
Beichen West Road, Chaoyang District,
Beijing 100105, P R China
Tel: +86 10 8437 2008
Fax: +86 10 8437 0387
Email: cncc@cnccchina.com
Reservation Please Contact
Tel: +86 10 8437 0690
Fax: +86 10 8437 0691
Email: rv@cnccchina.com
http://www.cnccchina.com/en/hotel/default.aspx
The CNCC Grand Hotel is international standard 420 room property that is immediately adjacent to the China International Convention Center on the Olympic Green boulevard. It serves as the CNCC host hotel for most CNCC events.
ABOUT US
The APHCON (Asia-Pacific Hematology Consortium) is the official host of BTG2015 and presents the 6th International Hematologic Malignancies Conference: Bridging the Gap 2014 with our logistics partner, The Medal Group. Founded in 2007, the Society is a non-profit medical association committed to promoting discourse about and furthering the research of hematology.
HISTORY
After the great success of BTG2010, BTG2011, BTG2012, BTG2013 and BTG2014, we present the 6th international educational meeting in Asia devoted to "Hematologic Malignancies: Bridging the Gap 2015" to be held in Beijing, China on January 31-February 1, 2015. The Congress brings together leading authorities in Hematology Oncology to present the latest ground breaking findings on cutting edge research and novel treatments. The discussion forums provide an opportunity to integrate the latest pharmaceutical interventions. The conference targets hematologic malignancies in particular leukemia, lymphoma, and myeloma. The target audience is Southeast and Central Asia, Japan, Australia and the United States.
The BTG series is being held in the South East Asia sector since the year 2010. The very first conference was held in Singapore attended by 250 delegates and now has grown to the most important meeting in this region. The conference has been held in Hong Kong for year 2012 and 2013; in Taipei for year 2014 and BTG2015 will be held in Beijing in year 2015.
In its 5th year, BTG2014 was attended by over 350 delegates from 19 different countries. In addition small breakout sessions were held in the format of simultaneous workshops that were a great success among the attendees. There were over 100 submitted abstracts and one oral presentation was chosen for the plenary session. In addition, all the selected abstracts are published in the peer reviewed journal ‘Leukemia & Lymphoma’. BTG2014 also afforded platform APHCON Presidential dinner and follow up of Preceptorship award.
What is G.A.P?
Global Academic Programs (GAP) facilitates and administers MD Anderson's Sister Institution Network; the largest global network of cancer centers working collaboratively on research and education aimed at lessening the world's cancer burden.
You can stay informed by subscribing to GAP Connect, a weekly newsletter intended to engage and enable global collaborations in cancer research.
BRIDGING THE GAP - 2015
This congress will be a productive, interactive and educational experience for the attendees. Top researchers and practitioners from the world over will meet to discuss the current state - and future directions - of Hematologic Malignancies in the Asian sector and explore opportunities for collaborations in order to further the field. The event promises to be a unique medical education forum for the exchange of critical information as well as analyze the challenges faced by the practicing clinicians. It will feature didactic presentations and debates, in which experts will discuss some of the most challenging topics in leukemia, stem cell transplant and mobilization, myelodysplastic syndrome, lymphoma and myeloma, providing a thorough analysis of research breakthroughs and emerging data.
NEED ASSESSMENT BTG2015
1. Orientation to purpose and scope of the agenda:
Why the Project exists: Cancer is a leading cause of death in central and Southeast Asia. It is important to note that in most developed countries, cancer is the second largest cause of death after cardiovascular disease, and epidemiological evidence points to this trend emerging in the less developed world. This is particularly true in countries in "transition" or middle-income countries, such as in South America and Asia. Already more than half of all cancer cases occur in developing countries. Cancer alone accounts for 16% of all deaths in Asia and Hematologic malignancies are an increasing subset of the total cancer incidence rate. In the recent years great improvement in the field of Oncology has taken place with a rapid growth in trained oncologists and cancer centers as well as advancements in diagnostic technology. However, since the Asian healthcare community is geographically dispersed, it is often characterized by a lack of standardization of treatment and different philosophies of care. Given this fragmentation, there is a need to formalize and integrate conceptual knowledge, disease understanding, therapeutic agent intervention, diagnostic methodologies, supportive care, and management of complications.
Since Beijing, China is on the leading edge of medicine and especially oncology care, it is an ideal venue for promoting stronger understanding between practitioners and laboratory researchers from different fields and providing a platform for advancing daily clinical practice. This would in turn improve overall quality of cancer treatment, especially in terms of diagnosis and follow up of therapeutic strategies.
The proposed conference ‘6th International Hematologic Malignancies Conference ‘Bridging the Gap:2015’’ in Beijing, China to be held on Jan 31-Feb 1, 2015 is the results of the joint effort of the MDACC, Houston and the Peking University, Beijing. The key objective of this meeting is to lay foundation of a potentially growing relationship between US and SouthEast Asia in the field of malignant Hematology.
The main goals include:
i) Identify the existing need for the current medical education of the practicing hematologists with an Asian perspective, and build sessions to address the key areas of need.
ii) Construct methodology for promoting increased awareness, knowledge and integration of diagnostic tests into daily practice in the field of malignant hematology in the Asian sector including practice guidelines and the latest therapeutic agents.
iii) Encourage and provide opportunity for clinical and basic research in the field of malignant hematology.
2. How it is different: This is a unique, the first of its kind conference in Beijing where US and Asian speakers will share the same platform to address the local physicians and fellows in training. Create awareness regarding the disease concept, pathology, diagnosis, new therapeutic options and novel pharmaceutical interventions. This conference also, proposes to have open case discussions where the local physicians will get a chance to do case discussions in an open forum platform set up. This informal setting proposes to overcome any barriers and provide a conduit of open discussion, exchange of ideas, sharing of data and possible clinical collaborations. This congress will be an exciting, productive, interactive and educational experience for the attendees. Top researchers and practitioners from the world over will meet to discuss the current state – and future directions – of Hematologic Malignancies in the Asian sector and explore opportunities for collaborations in order to further the field. The event promises to be a unique medical education forum for the exchange of critical information as well as analyze the diagnostic and therapeutic challenges faced by the practicing clinicians. It will feature didactic presentations and debates, in which experts will discuss some of the most challenging topics in lymphoma, myeloma, immunotherapy and stem cell transplant, providing a thorough analysis of research breakthroughs and emerging data.
3. Strategic value is to supporters: Beijing, China has one of the fastest growing economies with a great opportunity for the pharmaceutical industry. Moreover, Beijing, China is very friendly to visitors and foreign nationals. It is very easy to travel to, easily accessible, strategically located in the center of Asia and Australia. Already, major US pharmaceuticals have established their centers in Beijing, China. By providing an educational platform, our supporters will gain an extra ordinary advantage over the competitors in terms of getting great exposure, able to deliver the updated data as well as educate the prescribing physicians about their product. Moreover, the conference will provide a unique and credible interaction with the meeting delegates in order to establish long term relationships.
By supporting one of the biggest and the first truly international Hematologic Malignancies Conference in SouthEast Asia, the sponsors get exposure to over 750 attendees, most of who are from Beijing, China, India, China, Australia, Beijing, China, Japan, Malaysia, Thailand, Vietnam, Indonesia, Taiwan, UAE, UK, Middle east, and the United States. The sponsors get an opportunity to support promotional luncheons and dinner symposiums. Also, there is opportunity for exhibit booths, where the sponsors are able to directly get in touch with the local oncologists which otherwise maybe onerous. Therefore, with one contribution, the pharmaceutical companies are able to really get a return on their investment by getting a tremendous exposure, advertisement, marketing opportunity, gather demographic data, educate the practicing oncologists regarding their latest innovations and possibly get access to other wise hard to reach doctors.
4. Most important topics for the target audience: The incidence and prevalence of Hematologic Malignancies are on a great increase in Asia. The proposed topics cover the pathology, diagnostic procedures and latest treatments including stem cell transplant and post transplant maintenance therapy. Most of all the speakers are internationally acclaimed and of great repute which has already generated enough enthusiasm that the RSVP to the SAVE THE DATE announcements has reached a number close to 500 attendees. The proposed topics are in need of an in depth education and understanding and since these diseases are on the rise, it gives the target audience a great resource to learn from the major thought leaders in the field.
5. Confirmation of facility resources for sponsorship: exhibit space specs, available rooms and capacity for ancillary activities: the New Otani Hotel is one of the premier locations for conferences in China. The conference venue can hold upto 2,000 people with very grandiose facilities. Most of the international meeting attendees will be able to stay at the Convention hotel itself ensuring their easy access to the conference area. There are over 600 guest rooms for the meeting attendees. Also, there is availability of the foyer area for the exhibit booths and poster display. They also have enough space for break out sessions as well as Lunch symposiums.
6. Description of target audience, current registration, and demographics: This conference is specifically designed for Hematologists, Oncologists, Transplant Oncologists, Radiation Oncologists, physicians-in-training, and healthcare professionals (nurses, pharmacists, etc) involved in and/or interested in hematologic malignancies and their management. Attendees are expected to be from Beijing, China, India, China, Hongkong, Australia, Beijing, China, Japan, Malaysia, Thailand, Vietnam, Indonesia, Taiwan, UAE, UK, Middle East, and the United States. The current pre-registration estimated number is around 1500.
7. Invited Speakers: Estimated 40 international and national experts (culled from a pool of ground-breaking researchers and practitioners) will address the congress.
8. CONFERENCE REGISTRATION INFORMATION: The registration fee to attend this conference includes two days of scientific sessions, workshops, lunch sessions, coffee breaks and corporate mini symposiums.
REGISTRATION FEE:
Regular Registration: NOV 16, 2014- JAN 18, 2015: USD 599
ON Site Registration: JAN30, 2015 - Feb 1, 2015: USD 699
REFUND POLICY: An administrative fee of USD 125 will be deducted from any cancellations made after NOV 30, 2014. No refunds will be made after January 15, 2015.
PRIVACY POLICY: All information collected during the registration process will remain confidential. No personal information will be shared. We take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. While we use encryption to protect sensitive information transmitted online, we also protect your information offline. Only employees who need the information to perform a specific job (for example, billing or customer service) are granted access to personally identifiable information. The computers/servers in which we store personally identifiable information are kept in a secure environment. We are the sole owners of the information collected on this site. We only have access to/collect information that you voluntarily give us via email or other direct contact from you. We will not sell or rent this information to anyone.